A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

NCT06317311 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma

Interventions

BIOLOGICAL: Dostarlimab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

GlaxoSmithKline